Ziqiang Tian

机构：Hebei Medical University, Fourth Hospital of Hebei Medical University · ORCID：0009-0008-3570-854X

发表论文 26 篇 · 总被引 351 次 · h-index 10

代表论文

• Comparing a PD-L1 inhibitor plus chemotherapy to chemotherapy alone in neoadjuvant therapy for locally advanced ESCC: a randomized Phase II clinical trial (2023 · BMC Medicine · 被引 48)
• Safety and efficacy of neoadjuvant treatment with immune checkpoint inhibitors in esophageal cancer: real-world multicenter retrospective study in China (2022 · Diseases of the Esophagus · 被引 42)
• Identification of the key transcription factors in esophageal squamous cell carcinoma (2018 · Journal of Thoracic Disease · 被引 41)
• Comparison of neoadjuvant immunotherapy plus chemotherapy versus chemotherapy alone for patients with locally advanced esophageal squamous cell carcinoma: A propensity score matching (2022 · Frontiers in Immunology · 被引 40)
• Soluble c-Met Is a Reliable and Sensitive Marker to Detect c-Met Expression Level in Lung Cancer (2015 · BioMed Research International · 被引 32)
• Neoadjuvant Sintilimab Plus Chemotherapy in Resectable Locally Advanced Esophageal Squamous Cell Carcinoma (2022 · Frontiers in Oncology · 被引 31)